FY2024 Earnings Estimate for Femasys Issued By HC Wainwright

Femasys Inc. (NASDAQ:FEMY) – Stock analysts at HC Wainwright dropped their FY2024 earnings estimates for shares of Femasys in a note issued to investors on Tuesday, February 11th. HC Wainwright analyst E. Bodnar now anticipates that the company will post earnings of ($0.87) per share for the year, down from their prior forecast of ($0.84). HC Wainwright currently has a “Buy” rating and a $12.00 price target on the stock. The consensus estimate for Femasys’ current full-year earnings is ($0.84) per share. HC Wainwright also issued estimates for Femasys’ Q4 2024 earnings at ($0.25) EPS, FY2025 earnings at ($0.68) EPS, FY2026 earnings at ($0.39) EPS, FY2027 earnings at ($0.32) EPS and FY2028 earnings at ($0.19) EPS.

Separately, Chardan Capital lowered their price objective on shares of Femasys from $10.00 to $8.00 and set a “buy” rating on the stock in a research report on Wednesday, November 13th.

Femasys Stock Performance

Shares of FEMY opened at $1.59 on Friday. The company’s 50 day moving average price is $1.15 and its 200 day moving average price is $1.13. Femasys has a 52 week low of $0.86 and a 52 week high of $2.40. The company has a market capitalization of $36.41 million, a PE ratio of -1.96 and a beta of -2.81. The company has a debt-to-equity ratio of 0.86, a quick ratio of 3.26 and a current ratio of 3.94.

Femasys (NASDAQ:FEMY) last released its earnings results on Tuesday, November 12th. The company reported ($0.24) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($0.04). The firm had revenue of $0.55 million during the quarter, compared to analysts’ expectations of $0.40 million. Femasys had a negative return on equity of 141.49% and a negative net margin of 1,435.77%.

Institutional Trading of Femasys

A number of institutional investors and hedge funds have recently modified their holdings of the company. Jane Street Group LLC acquired a new stake in shares of Femasys in the fourth quarter worth $30,000. Northern Trust Corp lifted its stake in shares of Femasys by 42.6% in the fourth quarter. Northern Trust Corp now owns 126,096 shares of the company’s stock worth $139,000 after buying an additional 37,675 shares during the last quarter. Geode Capital Management LLC lifted its stake in shares of Femasys by 4.7% in the fourth quarter. Geode Capital Management LLC now owns 216,164 shares of the company’s stock worth $238,000 after buying an additional 9,681 shares during the last quarter. Virtu Financial LLC acquired a new stake in shares of Femasys in the fourth quarter worth $25,000. Finally, XTX Topco Ltd lifted its stake in shares of Femasys by 123.9% in the third quarter. XTX Topco Ltd now owns 32,535 shares of the company’s stock worth $36,000 after buying an additional 18,004 shares during the last quarter. 65.27% of the stock is currently owned by institutional investors and hedge funds.

Femasys Company Profile

Femasys Inc, a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination.